3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
The global recombinant proteins market is projected to grow from $132 billion in 2023 to $203 billion by 2029, according to a recent BCC Research study. 4 July 2024
US biotech Moderna has received a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. 4 July 2024
British drugmaker GSK (LSE: GSK) and Germany's CureVac (Nasdaq: CVAC) have announced a restructuring of their collaboration into a new licensing agreement. 4 July 2024
LenioBio, a German biotech company focused on cell-free protein production, and UK-based enzymatic DNA production Touchlight have announced a supply agreement. 3 July 2024
UK life science incubator Syncona says it has committed $42.5 million (£33.5 million) to a $170 million (£134 million) Series B financing of its portfolio company Beacon Therapeutics 3 July 2024
The US Food and Drug Administration (FDA) approved Eli Lilly’s Kisunla (donanemab-azbt), once-monthly injection for IV infusion), Alzheimer's treatment . 3 July 2024
The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for certain adults with uncontrolled chronic obstructive pulmonary disease (COPD). 3 July 2024
US healthcare giant Johnson & Johnson (NYSE: JNJ) yesterday released encouraging new data on the overall survival benefit of its Carvykti (ciltacabtagene autoleucel; cilta-cel). 3 July 2024
Cartesian Therapeutics, a biotech seeking to develop mRNA cell therapies for autoimmune diseases, was trading nearly 20% lower early in Tuesday’s trading. 3 July 2024
Swedish Orphan Biovitrum, also known as Sobi, today announced the initiation of a rolling Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for SEL-212. 2 July 2024
The UK Bioindustry Association (BIA) has joined the European Biosolutions Coalition, an initiative established by several industry organisations to elevate the prominence of biosolutions on Europe’s agenda. 2 July 2024
Amylyx Pharmaceuticals (Nasdaq: AMLX) has acquired the rights to Eiger Biopharmaceuticals’ (Nasdaq: EIGR) experimental drug avexitide for $35.1 million. 2 July 2024
Shares in TRACON Pharmaceuticals have fallen by a third, after the San Diego-based firm announced the termination of work on its candidate envafolimab. 2 July 2024
Hungarian drugmaker Gedeon Richter says it has acquired BCI Pharma, a Belgium-based privately-owned biotech company, carrying out innovative research activity in a variety of women’s health conditions. 2 July 2024
Dutch life sciences venture capital firm Forbion has announced the hiring of Josh Brumm, former president and chief executive of Dyne Therapeutics, as a general partner. 1 July 2024
New data from the 4th interim analysis of the PEARL migraine prevention study with Ajovy (fremanezumab) suggests it may challenge the rationale for treatment pauses. 1 July 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.